PMID- 30450162
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220331
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 9
IP  - 82
DP  - 2018 Oct 19
TI  - Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis.
PG  - 35343-35355
LID - 10.18632/oncotarget.26223 [doi]
AB  - Anti-PD1 antibodies exhibit satisfactory efficacy in treating certain types of 
      lymphoma. We conducted this meta-analysis to explore subtypes benefiting from 
      this treatment and the best anti-PD1 therapeutic modalities. METHODS: A 
      quantitative meta-analysis was performed via a systematic search in PubMed, Web 
      of Science, and The Cochrane Library. The pooled overall response rate (ORR), 
      progression-free survival (PFS), complete remission rate (CRR), overall survival 
      (OS) and adverse events (AEs) were calculated and compared. Data were analyzed 
      using a random-effects meta-analysis to determine risk ratios. Heterogeneity 
      across studies was analyzed using Q and I(2) statistics. RESULTS: Thirteen 
      articles were selected, and 9 studies were included in the meta-analysis. There 
      was evidence of significant heterogeneity among the studies. According to PD-L1 
      expression subgroup analysis, the PD-L1-positive group exhibited significantly 
      better outcomes than the PD-L1-negative group (Z=5.481, p=0.000), with pooled 
      ORRs of 0.74 (95% CI: 0.67-0.81) and 0.2 (95% CI: 0.11-0.3), respectively. For 
      PD-L1-positive and PD-L1-negative patients, the pooled CRRs, PFS and OS were 0.21 
      (95% CI: 0.14-0.29), 0.76 (95% CI: 0.71-0.81) and 1.0 (95% CI: 0.98-1.0) and 0.05 
      (95% CI: 0.01-0.11), 0.20 (95% CI: 0.09-0.39) and 0.64 (95% CI: 0.45-0.80), 
      respectively; differences were all statistically significant (Z=2.248, p=0.025; 
      Z=3.555, p=0.000; and Z=3.039, p=0.002, respectively). The pooled incidence of 
      treatment-related all-grade AEs and grade-3/4 AEs was 0.84 (95% CI: 0.75-0.92) 
      and 0.21 (95% CI: 0.15-0.29), respectively. CONCLUSION: Patients with PD-L1 
      overexpression in relapsed or refractory lymphoma benefited more from anti-PD-1 
      therapy. Moreover, treatment with approved PD-1 inhibitors was well tolerated.
FAU - Geng, Zhe
AU  - Geng Z
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430030, P. R. China.
FAU - Xiao, Yi
AU  - Xiao Y
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430030, P. R. China.
FAU - Zhu, Xiao-Jian
AU  - Zhu XJ
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430030, P. R. China.
FAU - Ye, Cong
AU  - Ye C
AD  - Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical 
      College, Huazhong University of Science and Technology, Wuhan 430030, P. R. 
      China.
FAU - Zhou, Jian-Feng
AU  - Zhou JF
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430030, P. R. China.
LA  - eng
PT  - Journal Article
DEP - 20181019
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC6219677
OTO - NOTNLM
OT  - Anti-PD1 antibodies
OT  - clinical activity
OT  - lymphoma
OT  - meta-analysis
OT  - safety
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2018/11/20 06:00
MHDA- 2018/11/20 06:01
PMCR- 2018/10/19
CRDT- 2018/11/20 06:00
PHST- 2017/10/13 00:00 [received]
PHST- 2018/06/13 00:00 [accepted]
PHST- 2018/11/20 06:00 [entrez]
PHST- 2018/11/20 06:00 [pubmed]
PHST- 2018/11/20 06:01 [medline]
PHST- 2018/10/19 00:00 [pmc-release]
AID - 26223 [pii]
AID - 10.18632/oncotarget.26223 [doi]
PST - epublish
SO  - Oncotarget. 2018 Oct 19;9(82):35343-35355. doi: 10.18632/oncotarget.26223. 
      eCollection 2018 Oct 19.